- The condition, NASH, short for
- Madrigal showed in a phase 2 study with 73 patients that its treatment was better than placebo at reducing fat in the liver, and the treatment managed to resolve NASH in 27% of the patients who received treatment, compared to just 6% of those in the placebo group.
- Madrigal's stock was up 60% before markets opened on Thursday on the results.
ADVERTISEMENT
Drugmaker Madrigal just came out with some promising data for its treatment of NASH, a 'silent disease' millions are living with — and the stock is exploding
Madrigal showed in a phase 2 study with 73 patients that its treatment was better than placebo at reducing fat in the liver, and the treatment managed to resolve NASH in 27% of the patients who received treatment, compared to just 6% of those in the placebo group.
ADVERTISEMENT
Recommended articles
FOLLOW BUSINESS INSIDER AFRICA
ADVERTISEMENT
Recommended articles
Top 10 most valuable South African brands in 2024
Africa's giants play tug of war for the top economic spot
Morocco is making giant strides to become Africa's aviation manufacturing hub
Hackers test their ransomwares in less protected regions like Africa before striking richer nations: Report
Top social media platforms used for agriculture in Kenya - Survey
African countries with the fastest-growing military strength in 2024
3 African countries could play host to Russian diplomatic missions
Trends in online casino gaming in New Zealand
